NasdaqGS - Nasdaq Real Time Price USD
Alnylam Pharmaceuticals, Inc. (ALNY)
294.06 +5.88 (+2.04%)
At close: 4:00:01 PM EDT
292.09 -1.97 (-0.67%)
After hours: 4:51:19 PM EDT
Trade ALNY on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ALNY
- Previous Close
288.18 - Open
290.95 - Bid 302.62 x 100
- Ask 288.14 x 100
- Day's Range
288.85 - 303.46 - 52 Week Range
273.11 - 495.55 - Volume
1,274,646 - Avg. Volume
1,112,598 - Market Cap (intraday)
39.261B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
73.88 - EPS (TTM)
3.98 - Earnings Date (est.) Jul 30, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
436.32
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ALNY
26.05%
S&P 500 (^GSPC)
7.49%
1-Year Return
ALNY
9.52%
S&P 500 (^GSPC)
20.78%
3-Year Return
ALNY
52.61%
S&P 500 (^GSPC)
69.22%
5-Year Return
ALNY
69.31%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
38.48B
Enterprise Value
36.74B
Trailing P/E
72.41
Forward P/E
30.86
PEG Ratio (5yr expected)
0.49
Price/Sales (ttm)
9.20
Price/Book (mrq)
35.78
Enterprise Value/Revenue
8.57
Enterprise Value/EBITDA
42.44
Financial Highlights
Profitability and Income Statement
Profit Margin
12.55%
Return on Assets (ttm)
10.06%
Return on Equity (ttm)
90.36%
Revenue (ttm)
4.29B
Net Income Avi to Common (ttm)
537.99M
Diluted EPS (ttm)
3.98
Balance Sheet and Cash Flow
Total Cash (mrq)
3.01B
Total Debt/Equity (mrq)
276.20%
Levered Free Cash Flow (ttm)
204.71M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreAlnylam Earnings: Amvuttra Uptake Drives Sales; Durability of Demand in Focus Amid Competition
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice TargetNarrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 02/18/2026
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Alnylam Earnings: Milestone Year as Firm Turned Profitable; Demand for Amvuttra Drives Growth
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
RatingPrice Target